Immunotherapy Drug Proven Remarkably Successful Against Serious Stem Cell Transplant ComplicationFuturismGraft-versus-host disease (GvHD) is a condition that can develop in response to an allogeneic stem cell transplant or a reduced-intensity allogenei… Continue reading
American Council on Science and HealthGene Therapy Effectively Treats Hemophilia BAmerican Council on Science and HealthHemophilia is a genetic disorder that impairs the ability of blood to clot. Obviously this can be life-threatening in the case of an… Continue reading
Science Daily |
Possible master switch for programming cancer immunotherapy
Science Daily Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies. Writing in the journal Nature … |
FierceBiotech |
News of Note—Superstrong eye repair; gene therapy for ‘bubble boy’ disease; mapping genetic risks for brain disorders
FierceBiotech Now scientists at St. Jude Children’s Research Hospital have early evidence that a gene therapy they developed could be a promising cure for the disease. The therapy delivers a normal copy of IL2RG—the gene that becomes mutated to cause the disease … |
News-Medical.net |
CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive
Medscape ATLANTA — New longer-term clinical data with chimeric antigen receptor (CAR) T cells now reported for patients with refractory and relapsed non-Hodgkin’s lymphoma show that the responses are durable in about half of those treated, with the suggestion … CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patientsNews-Medical.net CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaPR Newswire (press release) Autolus presents data for pan-checkpoint blocking tech to restore CAR T-cells‘ functionEPM Magazine Popular Science –Medical Xpress all 22 news articles » |
Medscape |
CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive
Medscape ATLANTA — New longer-term clinical data with chimeric antigen receptor (CAR) T cells now reported for patients with refractory and relapsed non-Hodgkin’s lymphoma show that the responses are durable in about half of those treated, with the suggestion … New trials show cancer immunotherapy can be incredibly effective—and incredibly dangerousPopular Science CAR T-cell therapies drive outcomes in lymphoma, myelomaEurekAlert (press release) CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patientsNews-Medical.net Business Wire (press release) –Medical Xpress all 29 news articles » |
Medical Xpress |
Scientists discover possible master switch for programming cancer immunotherapy
Medical Xpress Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies. Writing in the journal Nature … |